{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T19:51:44Z","timestamp":1770753104113,"version":"3.50.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82072981, 82272649, 82303881, 82403855, 82403078"],"award-info":[{"award-number":["No. 82072981, 82272649, 82303881, 82403855, 82403078"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["No. 2023A1515010450, 2023A1515012903, 2022A1515110033"],"award-info":[{"award-number":["No. 2023A1515010450, 2023A1515012903, 2022A1515110033"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04284-w","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T22:29:17Z","timestamp":1767479357000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of induction chemotherapy with\/without PD-1 inhibitors followed by concurrent chemoradiotherapy in locally advanced head and neck squamous cell carcinoma"],"prefix":"10.1007","volume":"75","author":[{"given":"Yongchao","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zan","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kang","family":"Ning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taonong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weichao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingjie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"issue":"11","key":"4284_CR1","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.annonc.2020.07.011","volume":"31","author":"JP Machiels","year":"2020","unstructured":"Machiels JP et al (2020) Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 31(11):1462\u20131475","journal-title":"Ann Oncol"},{"key":"4284_CR2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","author":"F Bray","year":"2024","unstructured":"Bray F et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"4284_CR3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1056\/NEJMra1715715","volume":"382","author":"LQM Chow","year":"2020","unstructured":"Chow LQM (2020) Head and neck cancer. N Engl J Med 382(1):60\u201372","journal-title":"N Engl J Med"},{"issue":"9208","key":"4284_CR4","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0140-6736(00)90011-4","volume":"355","author":"JP Pignon","year":"2000","unstructured":"Pignon JP et al (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355(9208):949\u2013955","journal-title":"Lancet"},{"issue":"3","key":"4284_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1470-2045(13)70011-1","volume":"14","author":"R Haddad","year":"2013","unstructured":"Haddad R et al (2013) Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 14(3):257\u2013264","journal-title":"Lancet Oncol"},{"issue":"25","key":"4284_CR6","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1200\/JCO.2013.54.6309","volume":"32","author":"EE Cohen","year":"2014","unstructured":"Cohen EE et al (2014) Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol 32(25):2735\u20132743","journal-title":"J Clin Oncol"},{"issue":"11","key":"4284_CR7","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359(11):1116\u20131127","journal-title":"N Engl J Med"},{"issue":"31","key":"4284_CR8","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1200\/JCO.2017.76.2518","volume":"36","author":"Y Tao","year":"2018","unstructured":"Tao Y, Auperin A, Sire C, Martin L, Khoury C, Maingon P, Bourhis J (2018) Improved outcome by adding concurrent chemotherapy to cetuximab and radiotherapy for locally advanced head and neck carcinomas: results of the GORTEC 2007\u201301 phase III randomized trial. J Clin Oncol 36(31):3084\u20133090","journal-title":"J Clin Oncol"},{"issue":"27","key":"4284_CR9","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1200\/JCO.2013.53.5633","volume":"32","author":"KK Ang","year":"2014","unstructured":"Ang KK et al (2014) Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 32(27):2940\u20132950","journal-title":"J Clin Oncol"},{"issue":"32","key":"4284_CR10","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1200\/JCO.2016.68.1478","volume":"34","author":"LQM Chow","year":"2016","unstructured":"Chow LQM et al (2016) Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and\/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol 34(32):3838\u20133845","journal-title":"J Clin Oncol"},{"issue":"14","key":"4284_CR11","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1200\/JCO.2016.70.1524","volume":"35","author":"J Bauml","year":"2017","unstructured":"Bauml J et al (2017) Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm. Phase II Study. J Clin Oncol 35(14):1542\u20131549","journal-title":"Phase II Study. J Clin Oncol"},{"issue":"10212","key":"4284_CR12","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394(10212):1915\u20131928","journal-title":"Lancet"},{"issue":"19","key":"4284_CR13","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856\u20131867","journal-title":"N Engl J Med"},{"key":"4284_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00100-1","author":"JP Machiels","year":"2024","unstructured":"Machiels JP et al (2024) Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial. Lancet Oncol. https:\/\/doi.org\/10.1016\/S1470-2045(24)00100-1","journal-title":"Lancet Oncol"},{"issue":"16_suppl","key":"4284_CR15","doi-asserted-by":"publisher","first-page":"6013","DOI":"10.1200\/JCO.2025.43.16_suppl.6013","volume":"43","author":"Y Tao","year":"2025","unstructured":"Tao Y et al (2025) Long-term results of the randomized, phase 3 KEYNOTE-412 trial of pembrolizumab (pembro) or placebo (pbo) plus concurrent chemoradiotherapy (CRT) for unresected, locally advanced head and neck squamous cell carcinoma (LA HNSCC). J Clin Oncol 43(16_suppl):6013\u20136013","journal-title":"J Clin Oncol"},{"issue":"1","key":"4284_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1056\/NEJMoa2415434","volume":"393","author":"R Uppaluri","year":"2025","unstructured":"Uppaluri R et al (2025) Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer. N Engl J Med 393(1):37\u201350","journal-title":"N Engl J Med"},{"issue":"23","key":"4284_CR17","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1001\/jama.2020.7819","volume":"323","author":"LE Thomas","year":"2020","unstructured":"Thomas LE et al (2020) Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial. JAMA 323(23):2417\u20132418","journal-title":"JAMA"},{"issue":"2","key":"4284_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247","journal-title":"Eur J Cancer"},{"issue":"12","key":"4284_CR19","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.1177\/0962280220940334","volume":"29","author":"Y Zhou","year":"2020","unstructured":"Zhou Y et al (2020) Propensity score weighting under limited overlap and model misspecification. Stat Methods Med Res 29(12):3721\u20133756","journal-title":"Stat Methods Med Res"},{"issue":"1","key":"4284_CR20","first-page":"250","volume":"188","author":"F Li","year":"2019","unstructured":"Li F et al (2019) Addressing extreme propensity scores via the overlap weights. Am J Epidemiol 188(1):250\u2013257","journal-title":"Am J Epidemiol"},{"issue":"9","key":"4284_CR21","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1001\/jamacardio.2020.1855","volume":"5","author":"N Mehta","year":"2020","unstructured":"Mehta N et al (2020) Association of use of Angiotensin-converting enzyme inhibitors and Angiotensin II receptor blockers with testing positive for Coronavirus disease 2019 (COVID-19). JAMA Cardiol 5(9):1020\u20131026","journal-title":"JAMA Cardiol"},{"issue":"1","key":"4284_CR22","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s12885-021-08128-5","volume":"21","author":"M Bernadach","year":"2021","unstructured":"Bernadach M et al (2021) Predictive factors of toxicity of TPF induction chemotherapy for locally advanced head and neck cancers. BMC Cancer 21(1):360","journal-title":"BMC Cancer"},{"issue":"11","key":"4284_CR23","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1093\/jjco\/hyx115","volume":"47","author":"T Matoba","year":"2017","unstructured":"Matoba T et al (2017) Chemo-selection with docetaxel, cisplatin and 5-fluorouracil (TPF) regimen followed by radiation therapy or surgery for pharyngeal and laryngeal carcinoma. Jpn J Clin Oncol 47(11):1031\u20131037","journal-title":"Jpn J Clin Oncol"},{"issue":"23","key":"4284_CR24","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1200\/JCO.2012.47.7802","volume":"31","author":"P Blanchard","year":"2013","unstructured":"Blanchard P et al (2013) Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol 31(23):2854\u20132860","journal-title":"J Clin Oncol"},{"key":"4284_CR25","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.oraloncology.2019.06.015","volume":"95","author":"M Gau","year":"2019","unstructured":"Gau M et al (2019) Induction chemotherapy in head and neck cancers: results and controversies. Oral Oncol 95:164\u2013169","journal-title":"Oral Oncol"},{"issue":"9","key":"4284_CR26","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1017\/S0022215116008513","volume":"130","author":"V Noronha","year":"2016","unstructured":"Noronha V et al (2016) Response to docetaxel and cisplatin induction chemotherapy of locally advanced head and neck squamous cell carcinoma: a multicenter, non-comparative, open-label interventional pilot study. J Laryngol Otol 130(9):833\u2013842","journal-title":"J Laryngol Otol"},{"issue":"4","key":"4284_CR27","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1200\/JCO.22.01408","volume":"41","author":"AL Ho","year":"2023","unstructured":"Ho AL (2023) Immunotherapy, chemotherapy, or both: options for first-line therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma. J Clin Oncol 41(4):736\u2013741","journal-title":"J Clin Oncol"},{"key":"4284_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.03.008","author":"T Yasuda","year":"2024","unstructured":"Yasuda T, Wang YA (2024) Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development. Trends Cancer. https:\/\/doi.org\/10.1016\/j.trecan.2024.03.008","journal-title":"Trends Cancer"},{"key":"4284_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12539","author":"GR Khosravi","year":"2024","unstructured":"Khosravi GR et al (2024) Immunologic tumor microenvironment modulators for turning cold tumors hot. Cancer Commun. https:\/\/doi.org\/10.1002\/cac2.12539","journal-title":"Cancer Commun"},{"issue":"3","key":"4284_CR30","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.immuni.2018.03.004","volume":"48","author":"MD Wellenstein","year":"2018","unstructured":"Wellenstein MD, de Visser KE (2018) Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape. Immunity 48(3):399\u2013416","journal-title":"Immunity"},{"issue":"21","key":"4284_CR31","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1200\/JCO.21.02198","volume":"40","author":"B Burtness","year":"2022","unstructured":"Burtness B et al (2022) Pembrolizumab alone or with chemotherapy for recurrent\/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death ligand-1 combined positive score. J Clin Oncol 40(21):2321\u20132332","journal-title":"J Clin Oncol"},{"issue":"4","key":"4284_CR32","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.21.02508","volume":"41","author":"KJ Harrington","year":"2023","unstructured":"Harrington KJ et al (2023) Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study. J Clin Oncol 41(4):790\u2013802","journal-title":"J Clin Oncol"},{"issue":"17","key":"4284_CR33","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627\u20131639","journal-title":"N Engl J Med"},{"issue":"1","key":"4284_CR34","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1186\/s12885-021-08958-3","volume":"21","author":"X Zhu","year":"2021","unstructured":"Zhu X et al (2021) PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis. BMC Cancer 21(1):1195","journal-title":"BMC Cancer"},{"issue":"1","key":"4284_CR35","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12885-023-10605-y","volume":"23","author":"G Huo","year":"2023","unstructured":"Huo G et al (2023) Efficacy of PD-1\/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis. BMC Cancer 23(1):143","journal-title":"BMC Cancer"},{"issue":"7","key":"4284_CR36","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41573-021-00345-8","volume":"21","author":"AJ Korman","year":"2022","unstructured":"Korman AJ et al (2022) The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nat Rev Drug Discov 21(7):509\u2013528","journal-title":"Nat Rev Drug Discov"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04284-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04284-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04284-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T23:02:19Z","timestamp":1767481339000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04284-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["4284"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04284-w","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,3]]},"assertion":[{"value":"28 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"35"}}